Skip to main content

ARCH Venture Partners — Portfolio, Page 10

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

236
Companies
$31.9B
Total invested
$143.1M
Avg. check
23
Industries
Biotechnology 19Health Care 11Therapeutics 9Pharmaceutical 7Medical 6Life Science 3+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 217236 of 236
Biopalette
September 2020

Biopalette operates a platform designed to provide gene-editing techniques.

Agriculture · Kobe$9.5M Series A
Magnolia NeuroSciences
July 2020

Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.

Biotechnology · New York$18.4M Series Unknown
JW Therapeutics
June 2020

JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.

Biotechnology · Shanghai$100.0M Series B
Metacrine
September 2019

Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.

Biotechnology · San Diego$50.0M Debt Financing
One BioMed
July 2019

One BioMed is a medical diagnostics company.

Biotechnology · Singapore$5.0M Series A
BlackThorn Therapeutics
June 2019

BlackThorn Therapeutics is a clinical-stage neurobehavioral health company pioneering the next generation of artificial intelligence.

Artificial Intelligence (AI) · San Francisco$76.0M Series B
Genuity Science
November 2018

Genuity Science is a biotechnology company that offers clinco-omics data analysis solutions for researchers.

Analytics · Boston$200.0M Series C
Rodeo Therapeutics
November 2018

Rodeo Therapeutics is a developer of small-molecule therapies designed to promote regeneration and repair of multiple tissue types.

Biotechnology · Seattle$8.9M Series Unknown
Nebula Genomics
October 2018

Nebula Genomics leverages blockchain technology to eliminate middlemen and empower people to own their personal genomic data.

Biotechnology · San Francisco$4.3M Series A
KSQ Therapeutics
September 2018

KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.

Biopharma · Cambridge$80.0M Series C
ApoGen Biotechnologies
August 2018

ApoGen Biotechnologies, Inc. is a biotechnology company focused on the development of a new class of therapeutics.

Biotechnology · Seattle$4.0M Series A
Sienna Biopharmaceuticals
August 2018

Clinical development and commercialization of innovative aesthetics and medical dermatology products based on scientific breakthroughs

Biotechnology · Westlake VillagePost Ipo Equity
Nohla Therapeutics
July 2018

Nohla Therapeutics is a biotechnology company that develops a shelf alternative to bone marrow transplants.

Biotechnology · Seattle$11.0M Series B
Hua Medicine
March 2018

Hua Medicine is a clinical-stage, innovative drug development company in China.

Biotechnology · ShanghaiSeries E
Pioneer Square Labs
January 2018

Pioneer Square Labs is a studio that creates and launches technology startups.

Enterprise Software · Seattle$15.0M Series B
Semma Therapeutics
November 2017

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.

Biotechnology · Cambridge$114.0M Series B
TRELYS
April 2017

TRELYS is a biotechnology company based in San Francisco, California.

Biotechnology · San Francisco$80K Seed
Genomics Medicine Ireland
October 2016

Genomics Medicine Ireland is an Irish life sciences company conducting a study across Ireland of the human genome.

Biotechnology · Dublin$40.0M Series A
Juno Therapeutics
August 2014

Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.

Biotechnology · Seattle$134.0M Series B
Oncofactor
August 2013

Oncofactor develops cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Biotechnology · Seattle$1.0M Series Unknown

Where ARCH Venture Partners invests

Biotechnology19
Health Care11
Therapeutics9
Pharmaceutical7
Medical6
Life Science3

About ARCH Venture Partners's portfolio

How many companies has ARCH Venture Partners invested in?

ARCH Venture Partners has invested in 236 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does ARCH Venture Partners invest in?

ARCH Venture Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 23 different industry categories.

What is ARCH Venture Partners's largest investment?

Among tracked funding rounds, Genuity Science received $200.0M in a Series C round. ARCH Venture Partners's total known invested capital is $31.9B.

What is the average investment size for ARCH Venture Partners?

ARCH Venture Partners's average investment size is $143.1M across its portfolio of 236 companies.

What are ARCH Venture Partners's most recent investments?

Recent ARCH Venture Partners portfolio additions include Biopalette, Magnolia NeuroSciences, JW Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 236 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →